US Viral Vector and Plasmid DNA Manufacturing Market Size Likely to Grow at a CAGR of 20.1% By 2035

Market Size and Growth

The U.S. market of viral vectors and plasmid DNA manufacturing is estimated to have a market size of USD 3.1 billion in 2026 and increase to USD 10.88 billion in 2035 with an annual growth rate of 20.1% from 2026 to 2035.

U.S. Viral Vector and Plasmid DNA Manufacturing Market Revenue and Trends

The U.S. viral vectors and plasmid DNA production market consists of Adeno-Associated Virus (AAV), Lentivirus, Retrovirus, Adenovirus, and other vectors, which are used in gene therapy, cell therapy, vaccines, and research and development. Market is also witnessing a gradual growth scenario owing to the growing pipeline of gene and cell therapies, rising approvals of advanced treatment therapies and the growth of investment in biotechnology and biopharmaceuticals.

The increase in revenue is being achieved through technological advances in both upstream and downstream manufacturing and the expansion of CDMO and scalable commercial production. There is also the advantage of the market of a sustained level of product innovation in the sphere of the vehicle platform, stronger regulatory assistance, and better accessibility to the contract manufacturing solutions throughout the United States.

What Are the Factors that Play a Significant Role?

The key growth opportunities include the rising approval of gene and cell therapies in the U.S., the increase in investments made by biopharmaceutical companies, and the widespread use of complex therapies of rare diseases and cancer. The availability of technological progress in the production of viral vectors and plasmid DNA, such as the higher-yield AAV and lentiviral systems, scalable upstream and downstream systems, and automated manufacturing systems meeting GMP standards, has further spurred market development. It is also due in part to the increasing use of CDMOs, the proliferation of commercial-scale manufacturing plants and the favorable FDA regulations. Accessibility and efficiency are increasing due to strategic innovations, collaboration and flexible contract manufacturing services that are driving stable revenue growth in the market between 2026 and 2035.

Segment Insight

By Vector Type

Adeno-Associated Virus (AAV) vectors have the highest share as they have the best safety profile, widespread use in gene therapies, and have been approved in several commercials. Lentivirus vectors are extensively utilized in CAR-T and cell therapies, and they have high growth. Vectors of retrovirus and adenovirus have continued to be adopted in research and in the initial stages of clinical practice. Innovation in next-generation therapies and niche applications is making other emerging viral platforms attain attention.

By Application

Gene therapy takes the lead in the market due to the rising clinical pipelines and commercial approval to treat rare diseases. Cell therapy is growing at a fast pace, specifically CAR-T and TCR. Viruses Vaccines such as viral vectors based on COVID-19 and oncolytic vaccines are gradually increasing. Research and development are very vital since new vectors, designs of plasmids and process innovations keep coming up.

By Workflow Stage

The biggest portion is upstream processing since it is resource intensive and complex in the production of viral vectors and plasmid DNA. Downstream processing is becoming increasingly rapid due to the progress in purification and scale. Another step is fill and finish, which is crucial especially to clinical and commercial product preparation to be regulatory compliant and a quality product.

By Manufacturing Scale

First is clinical-scale production because most of the therapies are at an early level of development and testing. Large scale manufacturing is expanding at a tremendous pace with large scale approval and demand for a large-scale supply of vectors which are being backed with investments of large scale GMP plants.

By End User

The greatest end users are the biopharmaceutical companies because of in-house development of proprietary therapies. CDMOs are growing at a rapid pace, providing scalable outsourced solutions of manufacturing to small and mid-sized biotech companies. Viral vectors and plasmid DNA are used in academic and research institutions in preclinical research and technology development.

Report Scope

Recent Developments

• To handle increased clinical and commercial scale-up and supply and demand of multiple gene and cell therapy programs, in July 2024 Catalent, Inc. launched integrated plasmid DNA and viral vector services, which are designed to expedite process development, scale-up, and supply.

List of the prominent players in the US Viral Vector and Plasmid DNA Manufacturing Market:

• Thermo Fisher Scientific

• Catalent Inc.

• Lonza Group

• Charles River Laboratories

• FUJIFILM Diosynth Biotechnologies

• WuXi Advanced Therapies

• AGC Biologics

• Oxford Biomedica

• Virovek Incorporation

• RegenxBio Inc.

• Waisman Biomanufacturing

• Genezen

• Others

The US Viral Vector and Plasmid DNA Manufacturing Market is segmented as follows:

By Vector Type

• Adeno-Associated Virus (AAV)

• Lentivirus

• Retrovirus

• Adenovirus

• Others

By Application

• Gene Therapy

• Cell Therapy

• Vaccines

• Research & Development

By Workflow Stage

• Upstream Processing

• Downstream Processing

• Fill & Finish

By Manufacturing Scale

• Clinical Scale

• Commercial Scale

By End User

• Biopharmaceutical Companies

• Contract Development & Manufacturing Organizations (CDMOs)

• Academic & Research Institutes